anti-HER2 protease-activated T-cell-engager AMX-818
Term · Oncology and biomedicine · MLC-T-ONC-010755
A protease-activated prodrug T-cell-engager (TCE) composed of two tandem single chain variable fragments (scFvs) targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and CD3, a T-cell surface antigen, and conjugated, via a protease-cleavable linker, to two unstructured polypeptides (XTEN), with potential immunomodulating and antineoplastic activities. Double XTEN masking allows for universal masks that sterically hinder target binding of AMX-818 until cleaved by proteases; it also prolongs half-life. Upon intravenous administration of anti-HER2/CD3/XTEN protease-activated TCE AMX-818, the XTEN masks are proteolytically cleaved in the tumor microenvironment (TME) by dysregulated proteases at the base of the XTEN masks which releases the active TCE. The anti-HER2 scFv moiety targets and binds to HER2 expressed on tumor cells. The CD3 scFv moiety targets and binds to T cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. The XTEN masks allows specific activation of AMX-818 in the TME and limits systemic unmasking; this minimizes systemic toxicity and increases efficacy. In healthy tissues, where protease activity is tightly regulated, the HER2-XTENylated protease-activated T-cell-engager (XPAT) AMX-818 remains predominantly inactive.
| Identifier | MLC-T-ONC-010755 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | HER2-XPAT AMX-818; XTENylated protease-activated T-cell-engager AMX-818; prodrug TCE AMX-818; prodrug HER2-XPAT T-cell engager AMX-818; TCE AMX-818; masked HER2 TCE AMX-818; Xtenylated protease-activated TCE AMX-818 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010755",
"term": "anti-HER2 protease-activated T-cell-engager AMX-818",
"field": "Oncology and biomedicine",
"definition": "A protease-activated prodrug T-cell-engager (TCE) composed of two tandem single chain variable fragments (scFvs) targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and CD3, a T-cell surface antigen, and conjugated, via a protease-cleavable linker, to two unstructured polypeptides (XTEN), with potential immunomodulating and antineoplastic activities. Double XTEN masking allows for universal masks that sterically hinder target binding of AMX-818 until cleaved by proteases; it also prolongs half-life. Upon intravenous administration of anti-HER2/CD3/XTEN protease-activated TCE AMX-818, the XTEN masks are proteolytically cleaved in the tumor microenvironment (TME) by dysregulated proteases at the base of the XTEN masks which releases the active TCE. The anti-HER2 scFv moiety targets and binds to HER2 expressed on tumor cells. The CD3 scFv moiety targets and binds to T cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. The XTEN masks allows specific activation of AMX-818 in the TME and limits systemic unmasking; this minimizes systemic toxicity and increases efficacy. In healthy tissues, where protease activity is tightly regulated, the HER2-XTENylated protease-activated T-cell-engager (XPAT) AMX-818 remains predominantly inactive.",
"synonyms": [
"HER2-XPAT AMX-818",
"XTENylated protease-activated T-cell-engager AMX-818",
"prodrug TCE AMX-818",
"prodrug HER2-XPAT T-cell engager AMX-818",
"TCE AMX-818",
"masked HER2 TCE AMX-818",
"Xtenylated protease-activated TCE AMX-818"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-her2-protease-activated-t-cell-engager-amx-818/"
}
Record 1,863 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.